Literature DB >> 10941900

The immunological effects of taxanes.

O T Chan1, L X Yang.   

Abstract

In the past decade, taxanes have gained notoriety as promising chemotherapeutic agents against different forms of cancer. These molecules were initially characterized as mitotic inhibitors, and their anti-neoplastic actions were attributed to their ability to suppress cellular division via microtubule stabilization. Less appreciated is the observation that taxanes induce other biological effects, especially in the immune system. For example, taxanes are immunostimulatory against neoplasms, supporting the idea that these agents suppress cancer through several mechanisms and not solely through inhibiting cell division. In addition, these drugs potentially regulate other aspects of immune function, such as lymphocyte activation, giving further support to their immunomodulatory capacity. In summary, taxanes effect multiple actions and potentially have greater therapeutic application beyond cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10941900     DOI: 10.1007/s002620000122

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  53 in total

1.  Regulation of microtubule, apoptosis, and cell cycle-related genes by taxotere in prostate cancer cells analyzed by microarray.

Authors:  Yiwei Li; Xingli Li; Maha Hussain; Fazlul H Sarkar
Journal:  Neoplasia       Date:  2004 Mar-Apr       Impact factor: 5.715

2.  Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice.

Authors:  Lukas W Pfannenstiel; Samuel S K Lam; Leisha A Emens; Elizabeth M Jaffee; Todd D Armstrong
Journal:  Cell Immunol       Date:  2010-03-06       Impact factor: 4.868

3.  Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner.

Authors:  Tillmann Michels; Galina V Shurin; Hiam Naiditch; Alexandra Sevko; Viktor Umansky; Michael R Shurin
Journal:  J Immunotoxicol       Date:  2012-01-28       Impact factor: 3.000

Review 4.  The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.

Authors:  James W Hodge; Andressa Ardiani; Benedetto Farsaci; Anna R Kwilas; Sofia R Gameiro
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

5.  Drug-induced hyperploidy stimulates an antitumor NK cell response mediated by NKG2D and DNAM-1 receptors.

Authors:  Andrea Acebes-Huerta; Seila Lorenzo-Herrero; Alicia R Folgueras; Leticia Huergo-Zapico; Carlos Lopez-Larrea; Alejandro López-Soto; Segundo Gonzalez
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

Review 6.  Cytokines as biomarkers of nanoparticle immunotoxicity.

Authors:  Mahmoud Elsabahy; Karen L Wooley
Journal:  Chem Soc Rev       Date:  2013-06-21       Impact factor: 54.564

Review 7.  Enhancing efficacy of therapeutic vaccinations by combination with other modalities.

Authors:  James L Gulley; Ravi A Madan; Philip M Arlen
Journal:  Vaccine       Date:  2007-06-04       Impact factor: 3.641

8.  Differential effects of Paclitaxel on dendritic cell function.

Authors:  Justin John; Mohammed Ismail; Catherine Riley; Jonathan Askham; Richard Morgan; Alan Melcher; Hardev Pandha
Journal:  BMC Immunol       Date:  2010-03-19       Impact factor: 3.615

Review 9.  Therapeutic cancer vaccines in combination with conventional therapy.

Authors:  Mads Hald Andersen; Niels Junker; Eva Ellebaek; Inge Marie Svane; Per Thor Straten
Journal:  J Biomed Biotechnol       Date:  2010-06-29

Review 10.  Vaccines against human carcinomas: strategies to improve antitumor immune responses.

Authors:  Claudia Palena; Jeffrey Schlom
Journal:  J Biomed Biotechnol       Date:  2010-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.